|
1
|
Wickremaratchi MM, Ben-Shlomo Y and Morris
HR: The effect of onset age on the clinical features of Parkinson's
disease. Eur J Neurol. 16:450–456. 2009.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rizek P, Kumar N and Jog MS: An update on
the diagnosis and treatment of Parkinson disease. CMAJ.
188:1157–1165. 2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cui L, Hou NN, Wu HM, Zuo X, Lian YZ,
Zhang CN, Wang ZF, Zhang X and Zhu JH: Prevalence of Alzheimer's
disease and parkinson's disease in China: An updated systematical
analysis. Front Aging Neurosci. 12(603854)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tang Q, Wang C, Wu W, Cao Y, Chen G and Lu
J: China should emphasize key issues inherent in rational
medication management for the elderly. Biosci Trends. 15:262–265.
2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ng JSC: Palliative care for Parkinson's
disease. Ann Palliat Med. 7:296–303. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Armstrong MJ and Okun MS: Diagnosis and
treatment of Parkinson disease: A review. JAMA. 323:548–560.
2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pezzoli G and Zini M: Levodopa in
Parkinson's disease: From the past to the future. Expert Opin
Pharmacother. 11:627–635. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Vasta R, Nicoletti A, Mostile G, Dibilio
V, Sciacca G, Contrafatto D, Cicero CE, Raciti L, Luca A and Zappia
M: Side effects induced by the acute levodopa challenge in
Parkinson's disease and atypical parkinsonisms. PLoS One.
12(e0172145)2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Trist BG, Hare DJ and Double KL: Oxidative
stress in the aging substantia nigra and the etiology of
Parkinson's disease. Aging Cell. 18(e13031)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bai L, Li X, He L, Zheng Y, Lu H and Li J,
Zhong L, Tong R, Jiang Z, Shi J and Li J: Antidiabetic potential of
flavonoids from traditional Chinese medicine: A review. Am J Chin
Med. 47:933–957. 2019.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wang ZY, Liu JG, Li H and Yang HM:
Pharmacological effects of active components of chinese herbal
medicine in the treatment of Alzheimer's disease: A review. Am J
Chin Med. 44:1525–1541. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Akanda MR, Uddin MN, Kim IS, Ahn D, Tae HJ
and Park BY: The biological and pharmacological roles of polyphenol
flavonoid tilianin. Eur J Pharmacol. 842:291–297. 2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Song WY, Song YS, Ryu HW, Oh SR, Hong J
and Yoon DY: Tilianin inhibits MUC5AC expression mediated via
down-regulation of EGFR-MEK-ERK-Sp1 signaling pathway in NCI-H292
human airway cells. J Microbiol Biotechnol. 27:49–56.
2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jiang H, Fang J, Xing J, Wang L, Wang Q,
Wang Y, Li Z and Liu R: Tilianin mediates neuroprotection against
ischemic injury by attenuating CaMKII-dependent
mitochondrion-mediated apoptosis and MAPK/NF-κB signaling. Life
Sci. 216:233–245. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Cacabelos R: Parkinson's disease: From
pathogenesis to pharmacogenomics. Int J Mol Sci.
18(551)2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wakabayashi K, Tanji K, Odagiri S, Miki Y,
Mori F and Takahashi H: The Lewy body in Parkinson's disease and
related neurodegenerative disorders. Mol Neurobiol. 47:495–508.
2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cao M, Wu Y, Ashrafi G, McCartney AJ,
Wheeler H, Bushong EA, Boassa D, Ellisman MH, Ryan TA and De
Camilli P: Parkinson Sac domain mutation in synaptojanin 1 impairs
clathrin uncoating at synapses and triggers dystrophic changes in
dopaminergic axons. Neuron. 93:882–896 e5. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kim CY and Alcalay RN: Genetic forms of
Parkinson's disease. Semin Neurol. 37:135–146. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Bellou V, Belbasis L, Tzoulaki I,
Evangelou E and Ioannidis JP: Environmental risk factors and
Parkinson's disease: An umbrella review of meta-analyses.
Parkinsonism Relat Disord. 23:1–9. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Subramaniam SR and Chesselet MF:
Mitochondrial dysfunction and oxidative stress in Parkinson's
disease. Prog Neurobiol. 106-107:17–32. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kamat PK, Kalani A, Rai S, Swarnkar S,
Tota S, Nath C and Tyagi N: Mechanism of oxidative stress and
synapse dysfunction in the pathogenesis of Alzheimer's disease:
Understanding the therapeutics strategies. Mol Neurobiol.
53:648–661. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Filomeni G, De Zio D and Cecconi F:
Oxidative stress and autophagy: The clash between damage and
metabolic needs. Cell Death Differ. 22:377–388. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kim EK and Choi EJ: Pathological roles of
MAPK signaling pathways in human diseases. Biochim Biophys Acta.
1802:396–405. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kyriakis JM and Avruch J: Mammalian MAPK
signal transduction pathways activated by stress and inflammation:
A 10-year update. Physiol Rev. 92:689–737. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lu N and Malemud CJ: Extracellular
signal-regulated kinase: A regulator of cell growth, inflammation,
chondrocyte and bone cell receptor-mediated gene expression. Int J
Mol Sci. 20(3792)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Schattauer SS, Bedini A, Summers F,
Reilly-Treat A, Andrews MM, Land BB and Chavkin C: Reactive oxygen
species (ROS) generation is stimulated by κ opioid receptor
activation through phosphorylated c-Jun N-terminal kinase and
inhibited by p38 mitogen-activated protein kinase (MAPK)
activation. J Biol Chem. 294:16884–16896. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jiang H, Xing J, Fang J, Wang L, Wang Y,
Zeng L, Li Z and Liu R: Tilianin protects against
ischemia/reperfusion-induced myocardial injury through the
Inhibition of the Ca2+/calmodulin-dependent protein
kinase II-dependent apoptotic and inflammatory signaling pathways.
Biomed Res Int. 2020(5939715)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Jiang H, Ashraf GM, Liu M, Zhao K, Wang Y,
Wang L, Xing J, Alghamdi BS, Li Z and Liu R: Tilianin ameliorates
cognitive dysfunction and neuronal damage in rats with vascular
dementia via p-CaMKII/ERK/CREB and ox-CaMKII-dependent MAPK/NF-κB
pathways. Oxid Med Cell Longev. 2021(6673967)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Jiang H, Zeng L, Dong X, Guo S, Xing J, Li
Z and Liu R: Tilianin extracted from Dracocephalum moldavica
L. induces intrinsic apoptosis and drives inflammatory
microenvironment response on pharyngeal squamous carcinoma cells
via regulating TLR4 signaling pathways. Front Pharmacol.
11(205)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Mullin S and Schapira AH: Pathogenic
mechanisms of neurodegeneration in Parkinson disease. Neurol Clin.
33:1–17. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nagatsu T and Nagatsu I: Tyrosine
hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other
catecholamine-related enzymes, and their human genes in relation to
the drug and gene therapies of Parkinson's disease (PD): Historical
overview and future prospects. J Neural Transm (Vienna).
123:1255–1278. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhu Y, Zhang J and Zeng Y: Overview of
tyrosine hydroxylase in Parkinson's disease. CNS Neurol Disord Drug
Targets. 11:350–358. 2012.PubMed/NCBI View Article : Google Scholar
|
